New therapies in sickle cell disease

Lancet

Volumn 360, Issue 9333, 2002, Pages 629-631

  Vichinsky, Elliott ^a  

^a CHILDREN S HOSPITAL OAKLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ACENOCOUMAROL; ANTIBODY; ARGININE; ARGINYLGLYCYLASPARTIC ACID; AZACITIDINE; BETA GLOBIN; CLOTRIMAZOLE; DEFERIPRONE; ERYTHROPOIETIN; FATTY ACID DERIVATIVE; GLUTAMINE; HEMOGLOBIN F; HEPARIN; HYDROXYUREA; I KAPPA B; ICA 17403; INTEGRIN RECEPTOR; NITRIC OXIDE; NS 1652; NS 3623; POLOXAMER; PYROGLUTAMATE MAGNESIUM; SALAZOSULFAPYRIDINE; SHORT CHAIN FATTY ACID; VALPROIC ACID; VON WILLEBRAND FACTOR;

ANEMIA; BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; CELL TRANSPLANTATION; GENE THERAPY; HEMOGLOBIN DETERMINATION; HUMAN; HYPERCOAGULABILITY; PATHOPHYSIOLOGY; PH; PRIORITY JOURNAL; REVIEW; SICKLE CELL ANEMIA; STEM CELL; THROMBOSIS;

EID: 0037167227     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)09776-3     Document Type: Short Survey

References (26)

1. Solovey A.A., Solovey A.N., Harkness J., Hebbel R.P. Modulation of endothelial cell activation in sickle cell disease: a pilot study. Blood. 97:2001;1937-1941.
2. Tomer A., Harker L.A., Kasey S., Eckman J.R. Thrombogenesis in sickle cell disease. J Lab Clin Med. 137:2001;398-407.
3. Mankad VN, ed. Pediatric Pathology and Molecular Medicine. Jan-Feb Edn. London: Taylor & Francis, 2001.
4. Atweh G.F., Loukopoulos D. Pharmacological induction of fetal hemoglobin in sickle cell disease and beta-thalassemia. Semin Hematol. 38:2001;367-373.
5. Charache S., Terrin M.L., Moore R.D., et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med. 332:1995;1317-1322.
6. Pawliuk R., Westerman K.A., Fabry M.E., et al. Correction of sickle cell disease in transgenic mouse models by gene therapy. Science. 294:2001;2368-2371.
7. Koshy M., Dorn L., Bressler L., et al. 2-deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia. Blood. 96:2000;2379-2384.
8. Brugnara C., Gee B., Armsby C.C., et al. Therapy with oral clotrimazole induces inhibition of the Gardos channel and reduction of erythrocyte dehydration in patients with sickle cell disease. J Clin Invest. 97:1996;1227-1234.
9. De Franceschi L., Bachir D., Galacteros F., et al. Oral magnesium supplements reduce erythrocyte dehydration in patients with sickle cell disease. J Clin Invest. 100:1997;1847-1852.
10. Brugnara C., De Franceschi L., Beuzard Y. Erythrocyte-active agents and treatment of sickle cell disease. Semin Hematol. 38:2001;324-332.
11. Hebbel R.P. Blockade of adhesion of sickle cells to endothelium by monoclonal antibodies. N Engl J Med. 342:2000;1910-1912.
12. Hebbel R.P., Boogaerts M.A., Eaton J.W., Steinberg M.H. Erythrocyte adherence to endothelium in sickle-cell anemia. A possible determinant of disease severity. N Engl J Med. 302:1980;992-995.
13. Kumar A., Eckman J.R., Wick T.M. Inhibition of plasma-mediated adherence of sickle erythrocytes to microvascular endothelium by conformationally constrained RGD- containing peptides. Am J Hematol. 53:1996;92-108.
14. Lefkovits J., Topol E.J. Platelet glycoprotein IIb/IIIa receptor inhibitors in ischemic heart disease. Curr Opin Cardiol. 10:1995;420-426.
15. Udani M., Zen Q., Cottman M., et al. Basal cell adhesion molecule/lutheran protein. The receptor critical for sickle cell adhesion to laminin. J Clin Invest. 101:1998;2550-2558.
16. Hillery C.A., Du M.C., Montgomery R.R., Scott J.P. Increased adhesion of erythrocytes to components of the extracellular matrix: isolation and characterization of a red blood cell lipid that binds thrombospondin and laminin. Blood. 87:1996;4879-4886.
17. Tomer A., Kasey S., Connor W.E., Clark S., Harker L.A., Eckman J.R. Reduction of pain episodes and prothrombotic activity in sickle cell disease by dietary n-3 fatty acids. Thromb Haemost. 85:2001;966-974.
18. Orringer E.P., Casella J.F., Ataga K.I., et al. Purified poloxamer 188 for treatment of acute vaso-occlusive crisis of sickle cell disease: a randomized controlled trial. JAMA. 286:2001;2099-2106.
19. Morris C.R. Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease? Blood. 96:(suppl, part 1):2000;485a.
20. Morris C.R., Kuypers F.A., Larkin S., et al. Arginine therapy: a novel strategy to induce nitric oxide production in sickle cell disease. Br J Haematol. 111:2000;498-500.
21. Romero J.R., Suzuka S.M., Nagel R.L., Fabry M.E. Arginine supplementation of sickle transgenic mice reduces red cell density and Gardos channel activity. Blood. 99:2002;1103-1108.
22. Walters M.C., Patience M., Leisenring W., et al. Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia. Biol Blood Marrow Transplant. 7:2001;665-673.
23. La Nasa G., Giardini C., Argiolu F., et al. Unrelated donor bone marrow transplantation for thalassemia: the effect of extended haplotypes. Blood. 99:2002;4350-4356.
24. Styles L.A., Vichinsky E. Effects of a long-term transfusion regimen on sickle cell-related illnesses. J Pediatrics. 125:1994;909-911.
25. Nietert P.J., Abboud M.R., Silverstein M.D., Jackson S.M. Bone marrow transplantation versus periodic prophylactic blood transfusion in sickle cell patients at high risk of ischemic stroke: a decision analysis. Blood. 95:2000;3057-3064.
26. Tisdale J., Sadelain M. Toward gene therapy for disorders of globin synthesis. Semin Hematol. 38:2001;382-392.